Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

VVOS

V

Vivos Therapeutics, Inc. (VVOS)

NCM – Real vaqt narxi. Valyuta: USD

1.15

-0.04 (-3.36%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.18

+0.03 (2.44%)

Bozordan keyin: Mar 27, 2026, 6:11 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Videolar

No Data

There is no data to display

Press-relizlar

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

LITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health conditions, today announced that an a recent study published in the Journal of Clinical Medicine supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal (upper) dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in adults and children.

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share.